We also show that isoform-specific inhibition of TGFβ is equivalent to pan-TGFβ inhibition in controlling B16 and CT26 tumor growth and, in combination with immune checkpoint blockade, can lead to improved tumor responses. This evidence concerns the gene TGFB1 and neoplasm.